Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Serina Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Serina Therapeutics's position in the market.
Serina Therapeutics (NYSE:SER) announced the advancement of SER-270 (POZ-VMAT2i), a novel once-weekly injectable VMAT2 inhibitor for treating tardive dyskinesia (TD). The drug leverages Serina's proprietary POZ Platform™ technology to provide a long-acting alternative to daily oral medications.
The U.S. TD market, which exceeded $3.7 billion in sales in 2024, is projected to reach $5.4 billion by 2030. Currently, fewer than 30% of U.S. TD patients are diagnosed, with less than half receiving treatment. The company also plans to explore the drug's potential for treating chorea associated with Huntington's disease.
POZ-VMAT2i specifically targets underserved patients who struggle with daily medication adherence, institutionalized patients, and those with dysphagia, offering a potentially transformative solution in the VMAT2 inhibitor market.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its proprietary POZ Platform™ drug optimization technology, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. CEO Steve Ledger will engage in a fireside chat on Tuesday, July 29, 2025, at 2:00 p.m. ET during the two-day conference scheduled for July 29-30, 2025.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to a new non-executive employee. The inducement grant consists of options to purchase 12,500 shares of common stock, with an exercise price matching the closing price on June 18, 2025.
The Option Grant, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, aims to align employee interests with stockholders and was made in compliance with NYSE American's Company Guide Section 711(a).
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company, has announced its 2025 Annual Stockholders Meeting will be held on November 7, 2025. The specific time and location will be detailed in the company's definitive proxy statement to be filed with the SEC.
Due to the meeting date change of more than 30 days from the 2024 annual meeting anniversary, stockholder proposals under Rule 14a-8 must be submitted by 5:00 p.m. (Central Time) on August 15, 2025. For stockholder proposals and director nominations under the company's bylaws, submissions must be received between July 10, 2025, and August 9, 2025 at the company's Huntsville, Alabama headquarters.
Serina Therapeutics (NYSE American: SER) announced its CEO Steve Ledger will present at a FORCE Family Office investor webinar on June 26, 2025, at 12:00 p.m. ET. The presentation, titled "New Drug Optimization Platform to Transform Parkinson's Care," will focus on the company's drug candidate SER-252, a polymer conjugate of apomorphine designed to provide continuous dopaminergic stimulation for Parkinson's disease treatment.
The webinar will highlight the company's POZ Platform™ technology and its potential to improve safety, duration, and tolerability of Parkinson's treatments. The event will include a Q&A session hosted by FORCE Family Office CEO Steve Saltzstein.
Serina Therapeutics (NYSE: SER) has appointed Dr. Stephen Brannan to its Board of Directors. Dr. Brannan brings over 30 years of experience in neuroscience and neuropsychiatry drug development. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical development of KarXT, the first new schizophrenia treatment mechanism in over 30 years, which contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024.
Dr. Brannan's extensive experience includes senior leadership roles at Takeda, Novartis, Cyberonics, and Eli Lilly, where he directed clinical programs in various CNS conditions. He will support Serina's strategic development of long-acting CNS therapeutics using their proprietary POZ Platform™ technology. The company also announced the departure of Remy Gross from its Board, who will continue supporting the team in a consulting role.
Serina Therapeutics (NYSE: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to two new non-executive employees. The grants, totaling 15,000 shares of common stock, were made on March 20, 2025, with an exercise price matching the closing stock price on that date.
The Option Grants, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, will vest over four years: 25% after the first year and the remaining 75% in three equal annual installments, subject to continued employment. These grants were made as employment inducements in compliance with NYSE American's Company Guide Section 711(a).
Serina's proprietary POZ Platform™ technology enables drug optimization for their lead candidate.